Research programme: langerhans cell histiocytosis - Crucell/Johns Hopkins

Drug Profile

Research programme: langerhans cell histiocytosis - Crucell/Johns Hopkins

Alternative Names: Langerhans cell histiocytosis research programme - Crucell/Johns Hopkins

Latest Information Update: 27 Jan 2005

Price : $50

At a glance

  • Originator Crucell
  • Developer Crucell; Johns Hopkins University
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Histiocytosis

Most Recent Events

  • 27 Jan 2005 Discontinued - Preclinical for Histiocytosis in Netherlands (unspecified route)
  • 27 Jan 2005 Discontinued - Preclinical for Histiocytosis in USA (unspecified route)
  • 27 Sep 2002 Preclinical trials in Histiocytosis in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top